Literature DB >> 3011062

Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage.

J F Riou, M Gabillot, M Philippe, J Schrevel, G Riou.   

Abstract

It has recently been suggested that topoisomerases could be important targets for drugs used in several diseases. This prompted us to purify and characterize the topoisomerases I and II present in the erythrocytes of protozoan parasites of the genus Plasmodium, the causative agent of malaria, in order to later use these enzymatic systems in antimalarial drug assays. The topoisomerases were purified from Plasmodium berghei, a parasite of mouse red cells. The Plasmodium topoisomerase II consists of two subunits with a molecular weight of about 160K. The enzyme is ATP- and Mg2+-dependent. The conditions for the reactions of relaxation, unknotting, decatenation, and catenation were found to be similar to those observed with enzymes from other eukaryotic cells. The Plasmodium topoisomerase I is a monomeric enzyme with a Mr of 70K-100K. It is ATP-independent and K+- or Na-dependent. Mg2+ is not required for relaxation but stimulates the reaction. Topoisomerase II was more sensitive to drug action than topoisomerase I. The most active drugs were the ellipticine derivatives. The antimalarial drugs, currently used in human clinical therapy, were poor inhibitors. Some antitumoral drugs stimulated the double-stranded DNA cleavage activity of Plasmodium topoisomerase II, like that of mammalian topoisomerases II. Antimalarial drugs had no stimulating activity. It is therefore suggested that Plasmodium topoisomerases are not good targets for antimalarial drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011062     DOI: 10.1021/bi00355a001

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

1.  Cloning and characterization of a cDNA encoding topoisomerase II in pea and analysis of its expression in relation to cell proliferation.

Authors:  M K Reddy; S Nair; K K Tewari; Y Mudgil; B S Yadav; S K Sopory
Journal:  Plant Mol Biol       Date:  1999-09       Impact factor: 4.076

Review 2.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

Review 3.  In vitro assays used to measure the activity of topoisomerases.

Authors:  J F Barrett; J A Sutcliffe; T D Gootz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 4.  Biochemical characteristics and physiological significance of major DNA topoisomerases.

Authors:  J A Sutcliffe; T D Gootz; J F Barrett
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

5.  ATP-independent type II topoisomerase from trypanosomes.

Authors:  S Douc-Rasy; A Kayser; J F Riou; G Riou
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

6.  Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.

Authors:  Carmen K M Mak; Victor K L Hung; Joseph T Y Wong
Journal:  Chromosoma       Date:  2005-11-15       Impact factor: 4.316

7.  Glycosylated flavones as selective inhibitors of topoisomerase IV.

Authors:  F X Bernard; S Sablé; B Cameron; J Provost; J F Desnottes; J Crouzet; F Blanche
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 8.  DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery.

Authors:  Carlos García-Estrada; Christopher Fernández Prada; Celia Fernández-Rubio; Francisco Rojo-Vázquez; Rafael Balaña-Fouce
Journal:  Proc Biol Sci       Date:  2010-03-03       Impact factor: 5.349

9.  Structure-activity relationships and modes of action of 9-anilinoacridines against chloroquine-resistant Plasmodium falciparum in vitro.

Authors:  P Chavalitshewinkoon; P Wilairat; S Gamage; W Denny; D Figgitt; R Ralph
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum.

Authors:  César Ordóñez; Javier Alfonso; Rafael Balaña-Fouce; David Ordóñez
Journal:  J Biomed Biotechnol       Date:  2009-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.